{"acquisitions":[],"changes":[],"country":"ES","description":"Connecta Therapeutics is a clinical-stage biotech developing treatments for central-nervous-system disorders that lack therapies. It targets patients with neurodevelopmental and neurodegenerative diseases. Its differentiator is a first-in-class molecule, CTH120, in trials for Fragile X syndrome.","domain":"connectatx.com","employees":null,"founded":2019,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":41.38258,"lng":2.177073,"location":"Barcelona, Spain","multiples":[],"name":"CONNECTA THERAPEUTICS SL","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2635200,"connectionsAmong":[],"currency":"EUR","date":"2025-02-17","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"connectatx-com-2025-02-17-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"connectatx-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"connectatx.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://connectatx.com"},{"fact":"description","publisher":"connectatx.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://connectatx.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Nginx 1.28.0","Google Cloud CDN","Google Cloud"],"totalRaisedUsd":2635200,"traction":[],"updatedAt":"2026-05-08","valuations":[]}